Ertapenem

Generic Name
Ertapenem
Brand Names
Invanz, Ertapenem SUN
Drug Type
Small Molecule
Chemical Formula
C22H25N3O7S
CAS Number
153832-46-3
Unique Ingredient Identifier
G32F6EID2H
Background

Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.

Indication

Ertapenem is indicated to treat the following moderate to severe infections caused by susceptible bacteria in adult and pediatric patients (three months of age and older):

Ertapenem is also used in adults for the prophylaxis of surgical site infection following elective colorectal surgery.

Associated Conditions
Acute Gynecological Infection, Severe Community-acquired Pneumonia (sCAP), Surgical Site Infections, Acute, moderate Pelvic Infections caused by susceptible bacteria, Acute, severe susceptible bacteria Pelvic Infections, Moderate Community acquired pneumonia, Moderate Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Moderate Diabetic Foot Infection, Moderate Gynaecological infection caused by susceptible bacteria, Moderate Postpartum Endomyometritis caused by susceptible bacteria, Moderate Septic Abortion caused by susceptible bacteria, Moderate complicated Urinary Tract Infection caused by susceptible bacteria, Moderate complicated skin and skin-structure infections caused by susceptible bacteria, Severe Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Severe Diabetic Foot Infection, Severe Gynaecological infection caused by susceptible bacteria, Severe Postpartum Endomyometritis caused by susceptible bacteria, Severe Septic Abortion caused by susceptible bacteria, Severe complicated Urinary Tract Infection caused by susceptible bacteria, Severe complicated skin and skin-structure infections caused by susceptible bacteria
Associated Therapies
-
Clinical Trials
Related News

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

First Posted Date
2022-12-09
Last Posted Date
2024-12-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
54
Registration Number
NCT05645757
Locations
🇺🇸

Altasciences Inc - Kansas City, Overland Park, Kansas, United States

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

Withdrawn
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Ertapenem
First Posted Date
2022-02-24
Last Posted Date
2022-02-24
Lead Sponsor
Henry Ford Health System
Registration Number
NCT05255575
Locations
🇺🇸

Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard,, Detroit, Michigan, United States

Combination Cefazolin with Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

First Posted Date
2021-05-14
Last Posted Date
2024-11-28
Lead Sponsor
Todd C. Lee MD MPH FIDSA
Target Recruit Count
60
Registration Number
NCT04886284
Locations
🇨🇦

Foothills Medical Centre, Calgary, Alberta, Canada

🇨🇦

Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital), Hamilton, Ontario, Canada

🇨🇦

Niagara Health - Niagara Falls Site, Niagara Falls, Ontario, Canada

and more 1 locations

A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

First Posted Date
2020-08-10
Last Posted Date
2020-08-10
Lead Sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Target Recruit Count
112
Registration Number
NCT04505683
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

First Posted Date
2020-08-06
Last Posted Date
2024-07-17
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
89
Registration Number
NCT04502095
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Antibiotic Prophylaxis in Patients Undergoing GVO

Phase 4
Recruiting
Conditions
Fever
Gastric Varix
Sepsis
Liver Cirrhoses
Interventions
Drug: Ertapenem
First Posted Date
2019-10-28
Last Posted Date
2019-10-28
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
150
Registration Number
NCT04140578
Locations
🇨🇳

Veteran General Hospital-Taipei, Taipei, Taiwan

Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

First Posted Date
2019-04-24
Last Posted Date
2023-03-29
Lead Sponsor
Phramongkutklao College of Medicine and Hospital
Target Recruit Count
427
Registration Number
NCT03925402
Locations
🇹🇭

Phramongkutklao Hospital, Bangkok, Thailand

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

First Posted Date
2018-12-28
Last Posted Date
2022-07-25
Lead Sponsor
Spero Therapeutics
Target Recruit Count
1372
Registration Number
NCT03788967
Locations
🇷🇺

Medical facility, Saint Petersburg, Russian Federation

🇺🇦

Medical Facility, Zhytomyr, Ukraine

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

First Posted Date
2017-11-30
Last Posted Date
2020-12-29
Lead Sponsor
Iterum Therapeutics, International Limited
Target Recruit Count
1395
Registration Number
NCT03357614
Locations
🇱🇻

Medical Facility, Valmiera, Latvia

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

First Posted Date
2017-11-30
Last Posted Date
2020-12-01
Lead Sponsor
Iterum Therapeutics, International Limited
Target Recruit Count
674
Registration Number
NCT03358576
Locations
🇵🇱

Medical Facility, Bielsk Podlaski, Poland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy